merck

With the majority of workers convinced that they will not receive Social Security and will be unable to retire, the market may be the best option for the future. Here's some ways to make stocks work for your retirement.

With an attractive balance sheet, healthy revenue growth and a solid return on equity, biotech company Celgene looks like a promising stock buy.

The pharmaceutical industry is ready to fall off a cliff -- a "patent cliff." Over the next few years, some of the world's most popular and lucrative medicines will go off patent, and generic competition will siphon an estimated quarter of a trillion dollars from drugmakers' bottom lines.

When Merck halted a late-stage study of its potential clot-preventing drug vorapaxar in stroke victims last week, it didn't explain why. Now, the company has confirmed it stopped the study after concerns that the drug increased the risk of bleeding in some patients.

Kenneth Frazier will be the new CEO of the pharmaceutical and health care giant, succeeding Richard Clark in January 2011.

Intel Capital has made a new set of investments through its $200 million Invest in America Technology Fund. Four software and chip-design businesses that have collectively received more than $30 million from the patriotic fund: Adaptive Computing, Ciranova, Joyent and Nexant.

Since the recession began, more than 8 million Americans have lost their jobs. But perhaps even more surprising is the small number of companies that are responsible for laying off such a large percentage of today's unemployed workers.

Two federal agencies are investigating whether drugmaker Merck & Co. violated the Foreign Corrupt Practices Act, which bars U.S. companies from bribing foreign officials.

Blue-chip earnings and an improvement in consumer sentiment helped stocks shrug off disappointing economic growth to end mixed Friday -- but the market still enjoyed its biggest monthly gain in a year.

Merck (MRK), the world's second largest drugmaker, said Thursday it plans to close eight manufacturing plants and eight research facilities around the world in its bid to save $3.5 billion a year. The Whitehouse Station, N.J.-based company is also reducing its workforce by 15%, or some 16,000...